Clinical and Translational Oncology

, Volume 12, Issue 12, pp 829–835

Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC)

  • Susana Cedrés Pérez
  • Isela Quispe
  • Pablo Martínez
  • Marina Longo
  • Eva Rodríguez
  • César Serrano
  • Eva Muñoz
  • Esther Pallisa
  • Enriqueta Felip
Research Articles



In stage I non-small-cell lung cancer (NSCLC) tumour size has been the most consistent determinant of survival. The choice of therapy option is based on accurate definition of the stage. The aim of our study is to correlate tumour size by computed tomography scan (CT) with pathologic size and to determine possible prognostic factors in surgically resected pathologic stage IA and IB NSCLC patients.


Retrospective review of CT scans and medical history data from 89 pathologic stage I NSCLC patients. Clinical prognostic factors analysed were age, gender, smoking status, pulmonary function, performance status (PS), surgical procedure, histopathology, vessel invasion, pleural infiltration, tumour size and number of lymph nodes resected. According to the new TNM classification for lung cancer, tumour size was divided into five groups (I: <2 cm, II: 2–3 cm, III: 3–5 cm, IV: 5–7 cm and V: >7 cm).


After a median surveillance of 55.2 months, 42 patients relapsed and 55 had died. The 5-year progressionfree survival was 55.7% and 5-year overall survival (OS) 49.9% (median 58.97 months). None of the clinical parameters analysed were predictors of OS. Significant correlation was found between tumour size in CT scan and pathologic stage (Pearson 0.75).


In our analysis with 89 surgically resected stage IA and IB NSCLC patients we found a good correlation between clinical and pathologic tumour size by CT scan. The prognoses factors analysed had no significant impact on survival.


Tumour size Prognostic factors Stage I Non-small-cell lung cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRefGoogle Scholar
  2. 2.
    Chansky K, Sculier JP, Crowley JJ et al (2009) The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4:792–801PubMedCrossRefGoogle Scholar
  3. 3.
    Martini N, Bains MS, Burt ME et al (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120PubMedCrossRefGoogle Scholar
  4. 4.
    Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111:1710–1717PubMedCrossRefGoogle Scholar
  5. 5.
    Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355:479–485 [Erratum, Lancet 2000;355:12]PubMedGoogle Scholar
  6. 6.
    Sobin LH, Wittekind Ch (eds) (2002) TNM classification of malignant tumours, 6th Edn. Wiley, New YorkGoogle Scholar
  7. 7.
    Groome PA, Bolejack V, Crowley J et al (2007) The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T,N and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:694–705PubMedCrossRefGoogle Scholar
  8. 8.
    Kawai H, Tada A, Kawahara M et al (2005) The Japan National Hospital Study Group for Lung Cancer. Smoking history before surgery and prognosis in patients with stage IA non small cell lung cancer — a multicenter study. Lung Cancer 49:63–70PubMedCrossRefGoogle Scholar
  9. 9.
    Nordquist LT, Simon GR, Cantor A et al (2004) Improved survival in never-smokers versus current smokers with primary adenocarcinoma of the lung. Chest 126:347–351PubMedCrossRefGoogle Scholar
  10. 10.
    Moro-Silot D, Aubert A, Diab S et al (2005) Comorbidities and Charlson score in resected stage I non-small cell lung cancer. Eur Respir J 26:480–486CrossRefGoogle Scholar
  11. 11.
    Berardi R, Brunelli A, Tamburrano T et al (2005) Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancer. Lung Cancer 49:371–376PubMedCrossRefGoogle Scholar
  12. 12.
    Berghmans T, Dusart M, Paesmans M et al (2008) Primary tumor standarized uptake value (SUV max) measured on fluordeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-anaysis by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3:6–12PubMedCrossRefGoogle Scholar
  13. 13.
    Gail MH, Eagan RT, Feld R et al (1984) Prognostic factors in patients with resected satge I nonsmall cell lung cancer. A report from the Lung Cancer Study Group. Cancer 54:1802–1813PubMedCrossRefGoogle Scholar
  14. 14.
    Lipford EH 3rd, Eggleston JC, Lillemoe KD et al (1984) Prognostic factors in surgically resected limited-stage, non-small cell carcinoma of the lung. Am J Surg Pathol 8:357–365PubMedCrossRefGoogle Scholar
  15. 15.
    Cagini L, Monacelli M, Giustozzi G et al (2000) Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 74:53–60PubMedCrossRefGoogle Scholar
  16. 16.
    Takise A, Kodama T, Shimosato Y et al (1988) Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 61:2083–2088PubMedCrossRefGoogle Scholar
  17. 17.
    Kwiatkowski DJ, Harpole DH Jr, Godleski J et al (1998) Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. J Clin Oncol 16:2468–2477PubMedGoogle Scholar
  18. 18.
    Raponi M, Zhang Y, Yu J et al (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66:7466–7472PubMedCrossRefGoogle Scholar
  19. 19.
    Raz DJ, Ray MR, Kim JY et al (2008) A multigene assay is prognostic of survival in patients with early stage lung adenocarcinoma. Clin Cancer Res 14:5565–5570PubMedCrossRefGoogle Scholar
  20. 20.
    Potti A, Mukherjee S, Peterson R et al (2007) A five-gene signature and clinical outcome in non-small cell lung cancer. N Engl J Med 356: 11–20CrossRefGoogle Scholar
  21. 21.
    Skrzypski M, Jassem E, Mendez P et al (2007) Expression profile of 29 genes by real-time quantitative PCR (RT-QPCR) in early-stage (I-IIIA) squamous cell carcinoma of the lung (SCCL). J Clin Oncol 25[Suppl]:abstract 7612Google Scholar
  22. 22.
    Tsao MS, Zhu C, Ding K et al (2008) A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. J Clin Oncol 26[Suppl]:abstract 7510Google Scholar
  23. 23.
    Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRefGoogle Scholar
  24. 24.
    Weatherall M, Marsh S, Shirtcliffe P et al (2009) Quality of life measured by the St George’s Respiratory Questionnaire and spirometry. Eur Respir J 33:1025–1030PubMedCrossRefGoogle Scholar
  25. 25.
    Strauss GM, Herndon JE, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043–5051PubMedCrossRefGoogle Scholar
  26. 26.
    Burdett S, Stewart LA, Rydzewska L (2006) A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 1:611–621PubMedCrossRefGoogle Scholar
  27. 27.
    Lardinois D, Weder R, Hany TF (2003) Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507PubMedCrossRefGoogle Scholar
  28. 28.
    Toloza EM, Harpole L, McCrory DC (2003) Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123:137S–146SPubMedCrossRefGoogle Scholar
  29. 29.
    Birim O, Kappetein AP, Stijnen T et al (2005) Meta-analyses of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in non-small cell lung cancer. Ann Thorac Surg 79:375–381PubMedCrossRefGoogle Scholar
  30. 30.
    Kelly RF, Tran T, Holmstrom A et al (2004) Accuracy and cost-effectiveness of [18F]-2-fluorodeoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 125:1413–1423PubMedCrossRefGoogle Scholar
  31. 31.
    Hoekstra CJ, Stroobandts SG, Hoekstra OS et al (2003) The value of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 39:151–157PubMedCrossRefGoogle Scholar
  32. 32.
    Fischer B, Lassen U, Mortensen J et al (2009) Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361:32PubMedCrossRefGoogle Scholar
  33. 33.
    Halpern BS, Schiepers C, Weber WA et al (2005) Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128:2289–2297PubMedCrossRefGoogle Scholar
  34. 34.
    Viney RC, Boyer MJ, King MT et al (2004) Randomized-controlled trial of the role positron emission tomography in the management of stage I and II non-small cell lung cancer. J Clin Oncol 22:2357–2362PubMedCrossRefGoogle Scholar
  35. 35.
    Port JL, Andrade RS, Levin MA et al (2005) Positron emission tomographic scanning in the diagnosis and staging of nonsmall cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg 130:1611–1615PubMedCrossRefGoogle Scholar
  36. 36.
    Cerfolio RJ, Bryant AS, Ojha B, Eloubeidi M (2005) Improving the inaccuracies of clinical staging of patients with NSCLC. A prospective trial. Ann Thorac Surg 80:1207–1214PubMedCrossRefGoogle Scholar
  37. 37.
    D’Cunha J, Herndon JE II, Herzan DL et al (2005) Poor correspondence between clinical and pathologic staging in stage I non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer 48:241–246PubMedCrossRefGoogle Scholar
  38. 38.
    Stiles BM, Servais EL, Lee PC et al (2009) Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg 137:13–19PubMedCrossRefGoogle Scholar
  39. 39.
    Hoang T, Xu R, Schiller JH et al (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 23:175–183PubMedCrossRefGoogle Scholar
  40. 40.
    Stanley K (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32PubMedGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  • Susana Cedrés Pérez
    • 1
  • Isela Quispe
    • 1
  • Pablo Martínez
    • 1
  • Marina Longo
    • 1
  • Eva Rodríguez
    • 1
  • César Serrano
    • 1
  • Eva Muñoz
    • 1
  • Esther Pallisa
    • 2
  • Enriqueta Felip
    • 1
  1. 1.Medical Oncology ServiceVall d’Hebron University HospitalBarcelonaSpain
  2. 2.Radiology DepartmentVall d’Hebron University HospitalBarcelonaSpain

Personalised recommendations